No Influence of APOE Status on Donanemab Efficacy 🔗 Access full article via Medscape NeurologyNew data from TRAILBLAZER-ALZ 2 show robust amyloid clearance with donanemab in APOE4 carriers and noncarriers, mitigating the risk of disease progression and dependency. Medscape Medical News Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
